Comparative Pharmacology
Head-to-head clinical analysis: EOHILIA versus TARPEYO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EOHILIA versus TARPEYO.
EOHILIA vs TARPEYO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EOHILIA (budesonide) is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines and arachidonic acid metabolites, thereby reducing inflammation in the esophagus.
TARPEYO (budesonide) is a corticosteroid with anti-inflammatory activity. It acts by binding to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines and immune cell activation, thereby reducing proteinuria in IgA nephropathy.
For adults: 0.5 mg/kg IV every 2 weeks, infused over 60 minutes. Maximum single dose: 40 mg.
16 mg/kg intravenously once daily on Days 1-5 of each 28-day cycle.
None Documented
None Documented
Terminal elimination half-life is 52 hours (steady state reached after 10-12 days of daily dosing)
Terminal elimination half-life is approximately 27.3 hours (range 21-36 hours) in patients with IgA nephropathy. This supports once-weekly subcutaneous dosing without dose adjustment over the dosing interval.
Renal (70% unchanged drug), fecal (12%) and biliary (5%)
Primarily hepatic metabolism, with <1% excreted unchanged in urine and <1% in feces. Elimination is predominantly via biliary excretion of metabolites into feces, accounting for >90% of total clearance.
Category C
Category C
Corticosteroid
Corticosteroid